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SUMMARY
Objectives—There are currently 94 known pneumococcal capsular polysaccharide serotypes and 
their prevalence differs by geographic region and the period studied. Streptococcus pneumoniae 
infections have been diagnosed clinically in Trinidad and Tobago and other Caribbean countries, 
however data on the serotype and sequence type distributions in this country are limited. The 
objective of this study was to determine serotypes and multilocus sequence types (MLSTs) of 
invasive and non-invasive pneumococcal isolates from Trinidad and Tobago.
Methods—Ninety-eight pneumococcal isolates from several regional hospitals in the country 
were analyzed using both standard microbiological methods and molecular analysis. These 
isolates included invasive (n = 83) and selected non-invasive (n = 15) strains recovered before (n = 
25) and after (n = 73) the introduction of the pneumococcal conjugate vaccine.
Results—More than half of the isolates (54.1%) were recovered from children under 15 years of 
age, with the largest proportion being from children under 2 years of age (24.5%). The most 
prevalent serotypes were 19F (18.4%), 6B (15.3%), 23F (14.3%), 3 (11.2%), 19A (6.1%), 6A 
(5.1%), 14 (5.1%), and 9V (4.1%). The most common serotype/MLST combinations were 6B/
ST138 (n = 10, 10.2%), 3/ST180 (n = 5, 5.1%), 23F/ST629 (n = 5, 5.1%), 19F/ST8398 (n = 4, 
4.1%), and three each of 6B/ST145, 14/9V/ST156, 9V/ST162, 19A/320, and 3/ST10440.
Conclusions—This report provides the first glimpse of the prevailing pneumococcal sequence 
types in the country. Most of the isolates represented serotypes in the 10-valent (61.2% of isolates) 
and 13-valent (83.7%) pneumococcal conjugate vaccines. A detailed population study is warranted 
to fully determine the circulating pneumococcal sequence types. Furthermore, the implementation 
of an effective and continuous surveillance system in Trinidad and Tobago is paramount to 
monitor vaccine impact.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
*Corresponding author. Tel.: +1 868 645 3232 ext. 2332; fax: +1 868 663 3797. peakpaka@yahoo.co.uk (P.E. Akpaka). 
HHS Public Access
Author manuscript
Int J Infect Dis. Author manuscript; available in PMC 2017 December 21.
Published in final edited form as:
Int J Infect Dis. 2016 May ; 46: 100–106. doi:10.1016/j.ijid.2016.04.005.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Keywords
Pneumococcal conjugate vaccine; Invasive pneumococcal disease; Sequence type; Multilocus 
sequence typing; Trinidad and Tobago
1. Introduction
Streptococcus pneumoniae continues to be a major cause of morbidity and mortality in 
humans.1–3 The spectrum of pneumococcal disease ranges from a mild respiratory illness to 
more severe diseases such as pneumonia and invasive pneumococcal diseases (IPD) such as 
bacteremia, sepsis, and meningitis. Pneumococcal disease is particularly common in young 
children under 2 years of age and adults over 65 years of age.1,4
There are currently 94 recognized capsular polysaccharide serotypes, including the recently 
reported serotypes 6C, 6D, 11E, and 20A/20B.2 Each serotype is distinguished based on the 
chemical composition of and antigenic differences in the capsular polysaccharide.2,3 Global 
surveillance has shown that only a limited number of capsular serotypes cause more than 
70–80% of IPD.4–6 The serotype distribution of IPD isolates differs somewhat by 
geographic region and the time period studied.4–6
Currently, there are two types of pneumococcal vaccine available on the global market: the 
pneumococcal polysaccharide vaccine (23-valent pneumococcal polysaccharide vaccine 
(PPV23), Pneumovax, Merck) and the pneumococcal conjugate vaccine (10-valent PCV10 
and 13-valent PCV13).3,5 PPV23 is recommended for use in the elderly and immune-
compromised individuals over the age of 2 years, while the PCVs are recommended for 
children under 2 years and also for older children. In late 2011, PCV13 was also 
recommended for adults ≥50 years who are clinically at risk, including adults over 65 years 
of age.2–4,7,8 PCV7 was formulated to include the most frequent serotypes causing pediatric 
IPD at that time in developed countries, in particular the USA (serotypes 4, 6B, 9V, 14, 18C, 
19F, and 23F).3,4,6,9 Two PCVs are currently available for use in children, PCV10 (PCV7 
serotypes plus 1, 5, and 7F; PHiD-CV, Synflorix, GlaxoSmithKline) and PCV13 (PCV7 
serotypes plus 1, 3, 5, 6A, 7F, and 19A; Prevnar, Pfizer); these replaced PCV7.3,4,7,8 The 
current vaccines provide wider serotype coverage than the previous PCV7 formulation.2,3,10
In the Caribbean, as well as other regions, vaccine uptake has been variable despite its 
approval for use. Although PCV7 was introduced in the USA in 2000, it was not until March 
2010 that it was introduced into the national immunization program (NIP) in Trinidad and 
Tobago for infants at risk of pneumococcal disease, mainly those with immune deficiencies 
and other chronic diseases. Prior to 2010, PCV7 was only available in the private sector for 
certain children with medical conditions that put them at higher risk of disease.11 In 2011, 
the PCV10 vaccine was introduced, followed by its widespread use in the NIP for all 
children aged <2 years.11–13 Subsequently, PCV13 was introduced into the NIP in August 
2015, replacing PCV10. Vaccine coverage with PCV10 was reported to be 95% as of 
December 2014.14
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PPV23 was licensed in Trinidad and Tobago in 2004, but was only incorporated into the NIP 
in 2012 for children over 2 years of age with chronic diseases, adults 65 years and above, 
and persons at risk of pneumococcal disease, including those with HIV/ AIDS.13,14 Trinidad 
and Tobago does not qualify for donor support under the Global Alliance for Vaccines and 
Immunizations (GAVI) program.15 However, vaccines are provided by the Trinidad and 
Tobago Government under their immunization program and are purchased through a Pan 
American Health Organization (PAHO) revolving fund.13
Although pneumococcal infections are clinically diagnosed and S. pneumoniae are routinely 
isolated from specimens, data on the serotype distribution in the Caribbean, and in Trinidad 
and Tobago in particular, are limited.11–13,16–23 The use of molecular methods to determine 
genotypes of strains in the Caribbean, as in many Latin American countries, has been 
limited due to financial constraints and other logistical difficulties.24 To the best of the 
authors’ knowledge, there is no published study that has used multilocus sequence typing 
(MLST) to characterize pneumococcal isolates from Trinidad and Tobago. The objective of 
this study was to characterize pneumococcal isolates from both invasive and selected non-
invasive sites using serotyping and MLST, and to compare these genotypes to well-described 
international clonal complexes (http://www.pneumogennet/pmen/).25
2. Materials and methods
2.1. Bacterial isolates and country demographics
All pneumococcal isolates (n = 73) obtained from routine clinical specimens submitted to 
the microbiology diagnostic laboratories of the five major public hospitals in Trinidad and 
Tobago, during the period 2011 to 2013, were included in this study. The isolates were 
included in the analysis if they met the following selection criteria: (1) patients with 
evidence of ongoing infection or confirmed diagnosis (clinical features including fever, 
elevated C-reactive protein, and elevated white cell count); (2) S. pneumoniae as the only 
pathogen isolated from both invasive and non-invasive sites. Duplicate isolates from the 
same episode of infection in any one patient were considered to represent the same episode, 
and therefore were counted once. Selected isolates from non-invasive sites were also 
included to ascertain a comprehensive picture of the molecular characteristics of 
pneumococcal infections.
A number of historical pneumococcal isolates (n = 25) from clinical specimens that were 
collected between 1997 and 2010 were also included in the analysis. Most of the strains 
were collected from three regional hospitals, prior to the commencement of the SIREVA 
(Sistema Regional de Vacinas), the Regional System for Vaccines in the Americas project in 
Trinidad and Tobago.11,26,27 These historical isolates were included to give some idea of the 
serotypes and sequence types present in the country prior to the introduction of the PCV7 in 
the vaccination program in Trinidad and Tobago. The isolates from the earlier period (1997–
1998) were not part of a specific study. The pre- and post-vaccination periods were defined 
as the years 1997 to February 2010 and March 2010 to 2013, respectively.
Demographic and clinical parameters were obtained using a standardized questionnaire. 
Conventional phenotypic identification was performed at the microbiology laboratories of 
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the regional hospitals in the country. The twin islands of Trinidad and Tobago are the most 
southern islands in the Caribbean, located just seven miles off the north eastern coast of 
Venezuela, and have an estimated population of 1.3 million. It is estimated that 19.4% of the 
population are less than 14 years old and 9.5% are 65 years old and above. About 13.7% of 
the population live in urban areas, with 66 000 people in the major capital city of Port of 
Spain. The majority (68.6%) of the population comprises people of African and Indian 
descent (34.2% and 34.4%, respectively), with people of mixed race, European, Chinese, 
and Middle Eastern ancestry adding diversity to the ethnic mix.28
All confirmed pneumococcal strains were collected and stored in brain–heart infusion broth 
with glycerol at −70 °C until further conventional and molecular analysis.
Ethical approval was obtained from the Ethics Committee of the University of the West 
Indies at St. Augustine. Permission was also granted by the ethics committees of all the 
regional hospitals where the studies were carried out, namely the North West Regional 
Health Authority, North Central Regional Health Authority, Eastern Regional Health 
Authority, South West Regional Health Authority, and Scarborough General Hospital 
Tobago. Patient records and information were anonymized and de-identified prior to 
analysis.
2.2. Capsular serotyping
All isolates were serotyped by conventional Quellung reaction method at the US Centers for 
Disease Control and Prevention (CDC) Streptococcus Laboratory (CDC, Atlanta, GA, 
USA). Further serotyping was performed using a sequential multiplex PCR method, as 
described by Pai et al., and updated on the CDC Streptococcus Laboratory website.29,30 
Genomic DNA was extracted from the bacterial isolates using Chelex 100 (Bio-Rad 
Laboratories, Hercules, CA, USA).
2.3. Multilocus sequence typing analysis
MLST was performed as described by Enright and Spratt, with modified primers (http://
www.cdc.gov/streplab/alt-mlst-primers.html).31 Briefly, the internal fragments of seven 
housekeeping genes (aroE, gdh, gki, recP, spi, xpt, and ddl) of the pneumococcal genome 
were amplified and sequenced, then the sequence types (STs) were determined by 
comparing the sequences with alleles from the pneumococcal MLST database (http://
pubmlst.org/spneumoniae/). New alleles and STs were submitted to the database curator for 
assignment. Clonal complexes were defined as groups of STs sharing ≥5 alleles with one or 
more members of the set and were assigned using eBURST version 3 program (http://
eburst.mlst.net) and arbitrarily assigned CC1–CC13.
3. Results
3.1. Bacterial isolates
Ninety-eight S. pneumoniae isolates were obtained; 83 were invasive isolates (from blood, 
pleural fluid, cerebrospinal fluid, and swab from brain tissue) and 15 were non-invasive 
isolates (ear, eye swabs, and sputum). Most of the invasive isolates were from blood (86.7%, 
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72/83), while the majority of the non-invasive isolates were from ear swabs (73.3%, 11/15). 
More than half of the isolates (54.1%, 53/98) were recovered from children under 15 years 
of age (Table 1), with the largest proportion being from children under 2 years of age 
(24.5%, 24/98). Twenty-five (25.5%) pneumococcal isolates were recovered before the 
introduction of the conjugate vaccines (1997 to February 2010) and 73 (74.4%) after (March 
2010 to 2013).
3.2. Serotype distribution
Twenty-two different serotypes were detected among the 98 isolates. Only eight serogroups/
serotypes were represented by at least four or more isolates (Table 1) and these accounted 
for 74.4% of the serotypes. These major serotypes included the following: 19F (18.4%), 6B 
(15.3%), 23F (14.2%), 3 (11.2%), 19A (6.1%), 6A (5.1%), 14 (5.1%), and 9V (4.1%). For 
the historical isolates (pre-PCV7 period, 1997–2010), the most prevalent serotypes in 
descending order were 19F (n = 7), 3 (n = 5), 6B (n = 4), 9V (n = 4), and 23F (n = 2); 7.1% 
were non-vaccine types (NVT). In the post-PCV7 period (March 2010 to 2013), serotypes 
19F, 23F, 6B, 3, 19A, and 6A were the most common, and 32.6% were NVT. Six serotypes 
(3, 6B, 11A, 14, 19F, and 23F) were identified in both periods. The total coverage rates of 
PCV7, PCV10, and PCV13 were 60.2%, 61.2%, and 83.7%, respectively; there was a 
significant 22.5% difference between PCV10 and PCV13 in coverage.
3.3. Clonal structure
The 98 pneumococcal isolates included in this study represented 55 different STs (Table 2). 
Nine STs accounted for more than 39.7% of the isolates, including ST138 (n = 10), ST180 
(n = 5), ST629 (n = 5), ST8398 (n = 4), and ST145, ST156, ST162, ST320, and ST10440 
(each accounting for three isolates). Fifteen (15.3%) new STs, including six new MLST 
alleles, were identified in this study and were assigned to ST 9743–9751, 10439, 10440, 
10446, 10449, 10450, and 10455 (Table 2). When compared with STs that have previously 
been deposited in the MLST database, eight of the 15 were related to previously reported 
STs. Of these 15 new STs, eight were identified during the period 1997–2009, including 
ST10440, which was also found during the post-vaccination period (2011–2013).
STs that represented more than one serotype included ST138 (6A, 6B, 19F), ST156 (9V, 14), 
and ST199 (15B, 19A). Twelve serotypes (4, 7F, 9N, 10A, 15A, 15B, 15C, 16F, 17F, 18C, 
22F, 35F) were associated with a single ST, whereas the remaining serotypes consisted of 
multiple STs. Serotypes 19F and 23F showed the most genetic diversity with 14 and eight 
STs, respectively. Four STs were isolated during both the pre- and post-PCV periods: STs 
62, 156, 180, and 10440. The eBURST analysis revealed 14 clonal complexes (CC) and 17 
singletons containing 63 and 35 isolates, respectively (Table 2). Of the new STs, five were 
singletons and 10 grouped into CCs. Fourteen isolates (14.3%) were identified as being 
related to seven of the internationally described Pneumococcal Molecular Epidemiology 
Network (PMEN) clones (PMEN3, PMEN4, PMEN14, PMEN31, PMEN37, PMEN38, and 
PMEN39; http://www.pneumogen.net/pmen/) (Figure 1).25
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4. Discussion
This study aimed to describe the observed prevailing serotypes and genotypes of 
pneumococcal isolates from both invasive and non-invasive pneumococcal diseases in 
Trinidad and Tobago. IPD is not a notifiable disease in Trinidad and Tobago, and the current 
laboratory-based surveillance system is based on voluntary rather than mandatory 
submission of isolates. The annual burden of pneumococcal disease in Latin America and 
the Caribbean has been estimated to be 1.6 million in children less than 5 years of age.32 In 
Trinidad and Tobago, the incidence rates of fever and acute respiratory infections (ARI) 
during the years 2009–2010 in ages less than 5 was 22 407–25, 202 cases per 100,000 and 
for ages over 5 years, it decreased from 2447–1163 cases per 100,000 for the same 
corresponding years.13
A number of pneumococcal infections in both children and adult patients were identified 
during the two time periods, before (1997 to February 2010) and after (March 2010 to 2013) 
PCV vaccination. A total of 98 isolates were available for analysis, with the majority 
recovered during the years 2011–2013. There were only 25 isolates available for the period 
1997–2010 (21 from 1997–1999 and four from 2007–2010), representing less than 2% of 
the pneumococcal isolates reported between 2007 and 2010.11–13,20,21 The majority of the 
isolates collected during these periods were not available for the current study analysis due 
to non-viability after storage. This is unfortunate, because it was a missed opportunity to 
further characterize samples prior to 2010.
The coverage rates of PCV7, PCV10, and PCV13 for pneumococcal isolates encountered in 
this study were 60.2%, 61.2%, and 83.7%, respectively. The observed 22.5% difference in 
PCV10 and PCV13 coverage rates is noteworthy. PCV10 provided little added benefit to 
PCV7, as two of the three serotypes (1 and 5) were rare in Trinidad and Tobago,11–13,16–22 
whereas the additional serotypes in PCV13 (3, 6A, and 19A) contributed to the increase in 
vaccine coverage that was observed. Data published by the SIREVA network and the 
Caribbean Public Health Agency (CARPHA), formerly the Caribbean Epidemiology Centre 
(CAREC), have shown that the most prevalent serogroups/serotypes causing IPD in the 
Caribbean prior to the NIP in Trinidad and Tobago were 14, 6B, 23F, 18, 19, 19F, 9, 6A, 1, 
and 23.16–20,22 Subsequently, serogroups 19 and 9 were identified as 19F and 9V, 
respectively, by the Instituto Nacional de Salud Bogotá, Bogotá, Colombia.22 During the 
same period in Trinidad and Tobago, 12 different serogroups and 22 serotypes were 
identified, the most prevalent being 14, 6B, 4, 6A, and 15C. Serotypes 14, 6B, 23F, and 4 
were recovered from children under 5 years of age.16–20,23 When compared globally to those 
observed in Latin America, North America, and Europe, the 10 prevalent serotypes prior to 
2010 in the present study were comparably well represented in samples from elsewhere in 
the pre-PCV7 and early post-PCV7 eras.2,5,6,9,22,26,33–37
Serotypes 1 and 5 were absent during the period 1997–2013 in the present analysis. This is 
similar to North America, where serotypes 1 and 5 are uncommon, but is different from the 
situation in some European, Asian, and Latin American countries, where they are frequently 
isolated.5,6,9,26,34,36–39 Serotype 6C, which has been identified in some countries,40–43 was 
absent in the isolates tested in the present study. It is unclear whether 6C may have been 
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among the serogroup 6A/6B isolates reported by CAREC from 1997 to 1999 and 2007 to 
2010, especially among those isolated after the introduction of PCV7.11–13,16–21 Studies in 
the USA have shown that previously typed 6A isolates recovered after PCV7 introduction 
were primarily 6C.40 Serotype 6C was first described in 2006, however retrospective 
analyses have indicated that it was in existence as early as 1962. Prior to PCV7, 6C was 
extremely rare in children <5 years old and was uncommon in adults.40–42,44 However, 6C 
increased overall with time throughout the 2000s to become the prevalent serogroup 6 
serotype within the US IPD surveillance.45 Serotype 6C emerged more significantly in 
adults than in children in the USA during this period,45 although carriage in children was 
seen to increase.46 Studies in Spain and other countries have shown similar increases in both 
children and adults, but at relatively low levels.42,47
In the present study, 27% of the 19F isolates were identified as 19F-var on PCR serotyping 
due to the wzy variant gene, which was first observed in Canada and Brazil.48–50 Identifying 
this variation in the serotype is important for accurate serotype determination in order to 
measure the impact of the vaccine. In this study, there was a marginal shift in the serotype 
distribution, including the emergence of NVTs in the post-PCV7/10 period, in particular 
serotype 19A. The emergence of 19A was observed globally in the post-PCV7 era, 
particularly in North America and many Asian countries.2,3,5,45 However, this serotype was 
also observed in some countries in the pre-PCV era.2,36,39 Not all vaccine serotypes provide 
cross-protection to other serotypes in the same group, as in the case of the 19F antigen in 
PCV7, which provides little or no protection against 19A.51 The increased use of both 
PCV10 and PCV13 in some countries has now resulted in decreases in these serotypes, 
including 19A and 7F, but continued increases in NVTs like 22F and 33F.51,52 In the present 
study, PCV7 NVT and PCV10 NVT increases in serotypes 3, 6A, serogroup 15, and 
serotype 11A were also seen, as has been reported from the USA and other developed 
countries.5,53 Now with the implementation of PCV13 in Trinidad and Tobago, it will be 
interesting to monitor the NVTs in the post-PCV13 period to assess changes in serotype due 
to increased valency.
The genotyping data using MLST showed great diversity among isolates from Trinidad and 
Tobago. While 55 different STs were identified, these were assigned to only 14 CCs and 
there were large numbers of singletons (n = 17). Also, 15.3% of isolates had new STs, which 
will provide the first MLST-based data for the Caribbean region. All new STs were from 
invasive sites, with the exception of one recovered from a sputum sample. Serotypes 19F and 
23F were more genetically diverse compared to the other serotypes and were associated with 
distinct STs, including nine of the new STs. Carriage studies have demonstrated that 19F, 
23F, and other ‘pediatric’ serotypes colonize the nasopharynx for longer periods as 
compared to serotypes like 1 and 7F, which colonize for a shorter duration.2,54,55 
Consequently, as they remain longer in the nasopharynx, there is sufficient opportunity for 
horizontal gene transfer between pneumococcal isolates and other nasopharyngeal 
organisms, which potentially contributes to this diversity.56
The occurrence of STs consisting of more than two serotypes due to horizontal transfer of 
capsule genes has been well documented,9,31,33 and there were several examples of capsular 
switching events in this study: ST138 (6A, 6B, 19F), ST156 (9V, 14), and ST199 (15B, 
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19A). Eight STs (138, 180, 629, 8398, 145, 156, 162, and 10440) accounted for more than 
36% of the isolates, and a number of isolates (14.3%) belonged to well-described 
international PMEN clones (http://www.pneumogen.net/pmen/). Of the 39 STs reported, 10 
from Latin American countries and 29 from North America have been deposited previously 
in the MLST database (http://pubmlst.org/spneumoniae/). Some of these STs have 
significant geographic spread, for example ST138 and ST180 have been found to be present 
in most regions, including the USA and some European and Latin American 
countries.2,24,33,57 ST629 has been observed in the USA30,58 and Germany (described in the 
MLST database). Available data on genotypes from Venezuela are limited, and the MLST 
database has 29 isolates deposited since 2007. Among these isolates, only three STs (ST320, 
ST156, and ST199) were similar to those from the Trinidad and Tobago study. Four STs 
were observed in both the pre- and post-vaccination periods (1997 to February 2010 and 
March 2010 to 2013): ST62, 156, 180, and 10440. ST62 (11A) was isolated both in 1998 
and 2012, and this ST has been described in invasive isolates from Spain and Italy 
(described in the MLST database).33
When the clonal composition was compared with the USA and Scotland in the pre- and the 
early post-vaccination periods, variations were observed. For instance, serotype 14 was 
represented by four STs in the USA and 12 STs in Scotland during the pre-PCV era, and 
quite striking was the absence of ST156 in Scotland.33,37,39 ST156 has frequently occurred 
worldwide and was first described as serotype 9V; this has subsequently also been described 
as serotype 14 and as other serotypes.25,57 Furthermore, ST156 is often associated with 
antibiotic resistance and is one of the well described PMEN clones (Spain9V-ST156, 
PMEN3) that have spread globally, including within the Latin America region.25 Isolates 
belonging to clonal complex 156 (CC156) were also found to modestly emerge within 19A 
in the post-PCV period in the USA.33 It is also interesting to see this very enduring clonal 
complex associated with several serotypes in the post-PCV13 era.59 In the present study, 
ST156 was associated with both serotype 9V and 14 (commonly found in South America), 
and CC156 included closely related ST8398 (19F), ST162 (9V), and ST10449 (14). PMEN4 
(Tennessee23F-ST37) was represented by nine STs, all of which were restricted to serotype 
23F.33
Six isolates were related to the highly successful Taiwan19F-ST236 (PMEN14) lineage, 
including ST320 (19A). In the USA, the ST320 complex was responsible for a dramatic 
increase in 19A IPD. 19A/ST320 and related 19A strains became the most commonly 
recovered strains from IPD during the 2006–2009 post-PCV7 era, and also constituted the 
majority of multi-resistant strains during this period.60 Putative vaccine escape ST695 19A 
variants (n = 2) of the non-resistant major PCV7 type 4 strain were also identified among the 
study isolates in the post-PCV7 period.60 Isolates belonging to other PMEN included 
serotype 15B and 19A capsular variant of Netherlands15B-ST199 (PMEN37), serotype 7F 
PMEN39 (Netherlands7F-ST191), serotype 4 PMEN38 (Sweden4-ST205), and five ST180 
serotype 3 isolates belonging to Netherlands3-ST180 (PMEN31). ST180 was isolated mainly 
from adults with IPD and was present during the pre-vaccination era and continued to 
circulate in 2013. One isolate from the pre-PCV7 period was recovered from a postmortem 
case in 1998. This ST180 clone is the major genotype of serotype 3 isolates globally, but 
independent lineages among type 3s in this study were also observed. In Europe and North 
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America, there have been reports of the ST180 clone associated with invasive diseases and 
increased mortality.33,37,61,62 ST1262 (15C), which was first observed in the USA study,33 
was also seen in the early post-PCV phase in the present study. The STs associated with 6B 
(138, 145, 146, 497, and 4241) were also different from those detected in Latin American 
countries.57
Some level of marginal shift in the serotype distribution appeared to be present in this study, 
including the emergence of the NVTs that have been observed globally. While data suggest 
the presence of a diverse array of genotypes, some well described global clones and their 
capsular variants described in other regions of the world, in particular North America, and 
mainly the USA, are also circulating in Trinidad and Tobago. The STs were slightly different 
from those in the neighboring Latin American country Venezuela, probably because the 
Venezuelan isolates have been less studied. This information will continue to provide 
baseline data for additional studies needed on the molecular characterization of 
pneumococcal isolates, not only in Trinidad and Tobago, but also throughout the Caribbean 
region.
One of the limitations of this study was the relatively small number of isolates used in the 
analysis, particularly for the pre-vaccination period (1997 to February 2010), which may not 
have reflected the true picture of circulating pneumococcal serotypes in Trinidad and 
Tobago. The isolates were recovered from patients seen and treated at the regional hospitals 
and this may have led to a bias towards the more severe cases. Despite these limitations, the 
information obtained from this study provides the first insight into the prevailing genotypes 
of pneumococcal isolates in the country. The findings also suggest that PCV13 could 
provide greater serotype coverage than PCV10 for serotypes currently causing IPD in 
Trinidad and Tobago. A more detailed population study is required post-PCV13 introduction 
in order to obtain a comprehensive picture of the circulating pneumococcal genotypes in the 
country.
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Figure 1. 
eBURST diagram showing a population snapshot of 98 isolates from Trinidad and Tobago 
with complete MLST data. Each ST is represented by a point, with the size of the point 
representing the number of isolates associated with that ST within the dataset. Isolates 
(14.3%) were related to seven of the internationally described PMEN clones (http://
www.pneumogen.net/pmen/). STs circled represent new STs identified among isolates in 
this study.
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Table 1
Age and serotype distribution of invasive and non-invasive pneumococcal isolates from Trinidad and Tobago
Age (years) No. of isolates (%) Serotype (No. of isolates)
<2 24 (24.5%) 6B (6), 9V (2), 14 (1), 19F (8), 23F (2), 3 (1), 10A (2), 16F (1), 22F (1)
2 to <5 18 (18.4%) 6B (4), 19F (3), 23F (5) 6A (2), 19A (3), 15C (1)
5 to <15 11 (11.2%) 14 (1), 19F (2), 23F (3), 3 (1), 6A (1), 15C (1), 18C (1)
15 to <24 1 (1.0%) 11A (1)
24 to <45 15 (15.3%) 9V (2), 6B (1), 14 (2), 19F (3), 23F (1), 3 (1), 19A (1), 11A (1), 15A (1), 17F (1), 35F (1)
45 to <60 11 (11.2%) 6B (2), 14 (1), 23F (2), 7F (1), 3 (2), 6A (1), 19F (1), 20 (1), 11A (1)
>60 18 (18.4%) 4 (1), 6B (2), 18C (1), 19F (1), 23F (1), 3 (6), 6A (1), 19A (2), 9N (1), 15B (1), 15A (1)
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Table 2
Distribution of genotype (ST) among the pneumococcal serotypes from Trinidad and Tobago, 1997–2013
Serotype No. of isolates Sequence type (No. of isolates) MLST_aroe-gdh-gki-recp-spi-xpt-ddl Clonal complex
4 1 205 10-5-4-5-13-10-18 Singleton
6B 15 138 (8) 7-5-8-5-10-6-14 Singleton
145 (3) 7-6-1-1-6-15-14 5
146 (2) 7-6-1-2-6-15-14 5
497 (1) 7-25-4-2-48-20-28 12
4241 (1) 15-16-19-10-6-20-26 Singleton
9V 4 156 (1) 7-11-10-1-6-8-1 2
162 (3) 7-11-10-1-6-8-14 2
14 5 156 (2) 7-11-10-1-6-8-1 2
554 (2) 8-8-4-15-39-12-26 Singleton
10449 (1) 7-11-10-1-451-8-1 2
18C 2 496 42-35-29-36-9-39-18 13
19F 18 138a (1) 7-5-8-5-10-6-14 Singleton
236 (1) 15-16-19-15-6-20-26 3
425 (1) 1-5-1-5-1-1-8 6
485 (2) 1-5-1-1-1-1-8 6
4251 (1) 15-16-19-10-6-20-26 3
793 (1) 7-13-9-1-6-19-14 11
3907 (1) 1-5-214-12-1-79-8 Singleton
6937 (1) 2-5-4-5-27-20-5 9
9743 (1) 1-5-106-12-10-4-14 Singleton
9744 (1) 15-16-19-15-6-4-26 3
9746 (1) 18-43-4-1-6-4-8 10
9748 (1) 18-5-4-1-6-11-8 10
8398a (4) 7-11-10-1-8-8-1 2
10450 (1) 327-5-4-5-27-20-5 9
23F 14 36 (2) 1-8-4-1-1-4-6 Singleton
37 (1) 1-8-6-2-6-4-6 1
439 (1) 1-8-9-2-6-4-6 1
629 (5) 1-8-9-10-6-4-6 1
9747 (1) 2-13-2-4-9-1-1 4
9749 (1) 1-8-9-6-6-4-6 1
9751 (1) 1-2-9-10-6-4-6 1
10446 (2) 1-8-9-294-6-4-6 1
7F 1 191 8-9-2-1-6-1-17 Singleton
3 11 180 (5) 7-15-2-10-6-1-22 Singleton
1116 (1) 1-26-28-11-13-1-14 14
662 (1) 5-35-29-12-9-39-18 13
10440 (3) 1-26-28-11-452-1-14 14
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Serotype No. of isolates Sequence type (No. of isolates) MLST_aroe-gdh-gki-recp-spi-xpt-ddl Clonal complex
10455 (1) 2-12-19-1-6-615-22 Singleton
6A 5 473 (2) 7-25-4-4-15-20-28 12
138 (1) 7-5-8-5-10-6-14 Singleton
460 (1) 5-7-4-10-10-1-27 7
490 (1) 2-13-9-1-6-19-14 11
19A 6 320 (3) 4-16-19-15-6-20-1 3
695 (2) 16-13-4-4-6-113-18 Singleton
9N 1 199 (1) 8-13-14-4-17-4-14 Singleton
66 2-8-2-4-6-1-1 4
10A 2 4753 5-241-4-2-10-1-27 7
11A 3 62 (2) 2-5-29-12-16-3-14 8
9750 (1) 2-5-29-12-16-1-14 8
15A 2 73 2-13-2-15-6-1-1 4
15B 1 199 8-13-14-4-17-4-14 Singleton
15C 2 1262 7-41-2-6-10-26-1 Singleton
16F 1 10439 1-10-62-10-15-1-31 Singleton
17F 1 392 7-5-1-1-6-31-14 5
20 1 9745 5-31-8-295-9-1-665 Singleton
22F 1 433 1-1-4-1-18-58-17 Singleton
35F 1 498 2-7-4-16-10-40-27 Singleton
STs underlined refer to new STs identified in this study. New alleles in this study are in bold.
a
These serotype 19F isolates are wzy variants described by Pimenta et al.48
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